Malaria kills 500,000 people every year. And 90 per cent of those are children. Griffith University researchers are screening hundreds of thousands of compounds supplied by Japanese companies to find the right compound with activity against the malaria parasite.

Japan’s Global Health Innovative Technology Fund is supporting the research as part of their search for new ways to fight malaria.

“GHIT is a fund that invests in partnerships between Japanese and non-Japanese entities,” says BT Slingsby, the Executive Director of GHIT.

“Many of those entities are in Australia including The University of Melbourne, The Walter and Eliza Hall Institute, and Griffith University.”

“Currently we’re working with companies such as Daiichi-Sankyo, Takeda, Mitsubishi Tanabe, and Eisai,” says Griffith University’s Vicky Avery. 

They bring those compounds to us. We then dispense them into plates which contain the parasite we’re trying to kill.  After they’ve been incubated for a period of time we then look to see whether they’ve had an effect in killing the parasites.

“Once one defines a hit, usually it’s the pharmaceutical company that drives forward the further development of that compound to create a drug.

“This collaboration is fantastic in that it has three groups who complement each other,” Vicky says.

The Japanese pharma companies bring expertise in drug discovery and development.  GHIT has managed to pull together significant funding from both global partners as well as the Japanese Government. And Griffith University brings the biology expertise.